Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
430 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,177 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 |
| clinicaltrials |
| NCT03418025 | Exercising Together During Radiation Treatment | completed | N/A | 24 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT04567875 | Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma(Apa-CARDIO1) | unknown | — | 54 | Ospedale Andrea Tortora di PaganiNETWORK | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02228265 | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | completed | — | 41 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT00064129 | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03406013 | Internet-Based Exercise and Diet Support in Prostate Cancer Survivors | completed | N/A | 206 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03504995 | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer. | completed | N/A | 10 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03596710 | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03934164 | Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO(MAESTRO) | unknown | — | 600 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT01664130 | High-Dose Stereotactic Radiation for Prostate Cancer | completed | N/A | 35 | Case Comprehensive Cancer CenterOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 12 | Pellficure Pharmaceuticals, IncINDUSTRY | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02991911 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer(MEDI3726) | completed | Phase 1 | 33 | MedImmune LLCINDUSTRY | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04225910 | Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer | unknown | Early Phase 1 | 20 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT04220398 | Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer | unknown | N/A | 475 | RenJi HospitalOTHER | 0 | Jan 7, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT02066961 | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer(ASPIRE-PCa) | completed | — | 1,533 | Astellas Pharma Global Development, Inc.INDUSTRY | 27 | Dec 20, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT02470910 | Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02381015 | Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a | completed | N/A | 700 | Endeavor HealthOTHER | 0 | Nov 22, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03326440 | Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer(VERT) | completed | N/A | 79 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Oct 10, 2019 | clinicaltrials |
| NCT00868595 | MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | completed | Phase 1 | 18 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT02426333 | Optimizing Abiraterone Therapy(OPTIMUM) | completed | — | 56 | Radboud University Medical CenterOTHER | 1 | Sep 13, 2019 | clinicaltrials |
| NCT03011749 | Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients | terminated | N/A | 6 | Rigshospitalet, DenmarkOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01737151 | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer | terminated | N/A | 19 | Virginia Commonwealth UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT02927899 | Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer | completed | N/A | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01981109 | Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer(PREDICT) | terminated | — | 225 | DendreonINDUSTRY | 1 | Aug 28, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2020source: clinicaltrials